{
    "nctId": "NCT00936442",
    "briefTitle": "Arimidex Therapy Compliance Electronic Monitoring System",
    "officialTitle": "ARimidex Therapy Compliance Electronic MonitorIng System. A Study to Evaluate the Impact of Educational Material on the Adherence to Treatment With Adjuvant Anastrozole for Postmenopausal Women With Hormone Sensitive Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Overall adherence to anastrozole",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with hormone sensitive early breast cancer.\n* Documented decision of treatment with anastrozole which will start in 13 weeks according to current SmPC OR current treatment with anastrozole according to current SmPC, that has not exceeded thirteen weeks before enrollment.\n* Subjects who accept to use MEMS\u00ae monitors to automatically compile their drug dosing histories.\n\nExclusion Criteria:\n\n* Concomitant or previous use of adjuvant tamoxifen, letrozole or exemestane for the current tumour.\n* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff or staff at the study site).\n* Participation in another clinical study with an investigational product during the last 3 months.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}